Noura Alkhayyal1,2,3, Iman Talaat1,3, Arya Vinodnadat3, Azzam Maghazachi4,3, Salah Abusnana4,2, Kari Syrjänen5, Riyad Bendardaf4,2. 1. College of Medicine, University of Sharjah, Sharjah, United Arab Emirates doctornoura@gmail.com italaat@sharjah.ac.ae. 2. University Hospital Sharjah, Sharjah, United Arab Emirates. 3. Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates. 4. College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. 5. Department of Clinical Research, Helsinki, Finland.
Abstract
BACKGROUND: Insulin-like growth factor 1 receptor (IGF1R) activation triggers multiple signaling pathways involved in proliferation and anti-apoptosis in breast cancer (BC). MATERIALS AND METHODS: Immunohistochemistry for IGF1R was performed on 50 BC cases; expression was assessed for staining intensity and localization pattern (mixed, membranous, and cytoplasmic) which was correlated to hormone receptor status. RESULTS: Of estrogen receptor-positive (ER+) cases, 97.2% were IGF1R+ (48.6% mixed, 43.2% membranous, and 5.4% cytoplasmic pattern) compared to ER- cases (38.5%, 7.7% and 30.8%, respectively) (p=0.003). In progesterone receptor-positive (PR+) cases, 97.2% were IGF1R+, (47.2%, 41.7% and 8.3%, respectively) compared to PR- ones (42.9%, 14.3% and 21.4%, respectively) (p=0.036). For human epidermal growth factor receptor 2-negative (HER2-) cases, 88.8% were IGF1R+ (44.4%, 8.3% and 36.1%, respectively). All HER2+ cases were IGF1R+ (71.4%, 7.1% and 21.4%, respectively) (p=0.015). In conclusion, hormone receptor-positive HER2- cases showed membranous and mixed IGF1R localization. However, hormone receptor-negative and HER2+ showed cytoplasmic or diminished IGF1R expression. CONCLUSION: These luminal subtypes may benefit from targeted IGFR therapy in the future. Copyright
BACKGROUND:Insulin-like growth factor 1 receptor (IGF1R) activation triggers multiple signaling pathways involved in proliferation and anti-apoptosis in breast cancer (BC). MATERIALS AND METHODS: Immunohistochemistry for IGF1R was performed on 50 BC cases; expression was assessed for staining intensity and localization pattern (mixed, membranous, and cytoplasmic) which was correlated to hormone receptor status. RESULTS: Of estrogen receptor-positive (ER+) cases, 97.2% were IGF1R+ (48.6% mixed, 43.2% membranous, and 5.4% cytoplasmic pattern) compared to ER- cases (38.5%, 7.7% and 30.8%, respectively) (p=0.003). In progesterone receptor-positive (PR+) cases, 97.2% were IGF1R+, (47.2%, 41.7% and 8.3%, respectively) compared to PR- ones (42.9%, 14.3% and 21.4%, respectively) (p=0.036). For humanepidermal growth factor receptor 2-negative (HER2-) cases, 88.8% were IGF1R+ (44.4%, 8.3% and 36.1%, respectively). All HER2+ cases were IGF1R+ (71.4%, 7.1% and 21.4%, respectively) (p=0.015). In conclusion, hormone receptor-positive HER2- cases showed membranous and mixed IGF1R localization. However, hormone receptor-negative and HER2+ showed cytoplasmic or diminished IGF1R expression. CONCLUSION: These luminal subtypes may benefit from targeted IGFR therapy in the future. Copyright
Authors: Noura Alkhayyal; Noha M Elemam; Amal Hussein; Sulaman Magdub; Majd Jundi; Azzam A Maghazachi; Iman M Talaat; Riyad Bendardaf Journal: Heliyon Date: 2022-08-30